TriangleLABELS · 381f1ba3-f115-424f-9890-75eb06ab6666
KYMRIAH
Open original source → · Download preserved record
Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.
- Label effective date
- 2025-12-16
- Captured
- 2026-09-09T23:37:44.904352+00:00
- Current indication reconciliation
- Not reconciled
Boxed warning in this label
- WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGICAL TOXICITIES, and SECONDARY HEMATOLOGICAL MALIGNANCIES Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving KYMRIAH. Do not administer KYMRIAH to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids [see Dosage and Administration (2.2, 2.3), Warnings and Precautions (5.1)]. Neurological toxicities, including severe or life-threatening reactions, occurred following treatment with KYMRIAH, including concurrently with CRS. Monitor for neurological events after treatment with KYMRIAH. Provide supportive care and/or corticosteroids as needed [see Warnings and Precautions (5.2)]. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19- directed genetically modified autologous T cell immunotherapies, including KYMRIAH [see Warnings and Precautions (5.8)]. WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGICAL TOXICITIES, and SECONDARY HEMATOLOGICAL MALIGNANCIES See full prescribing information for complete boxed warning. Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving KYMRIAH. Do not administer KYMRIAH to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids. ( 2.2 , 2.3 , 5.1 ) Neurological toxicities, including severe or life-threatening reactions, occurred following treatment with KYMRIAH, including concurrently with CRS. Monitor for neurological events after treatment with KYMRIAH. Provide supportive care and/or corticosteroids as needed. ( 5.2 ) T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19- directed genetically modified autologous T cell immunotherapies, including KYMRIAH. ( 5.8 )
Indications and usage: exact source text
- 1 INDICATIONS AND USAGE KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. ( 1.1 ) Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitations of Use : KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1.3 ) 1.1 Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia KYMRIAH is indicated for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. 1.2 Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitation of Use: KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma. 1.3 Adult Relapsed or Refractory Follicular Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies (14.3)] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Full extracted label fields
- application numbers
- BLA125646
- boxed warning exact
- WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGICAL TOXICITIES, and SECONDARY HEMATOLOGICAL MALIGNANCIES Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving KYMRIAH. Do not administer KYMRIAH to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids [see Dosage and Administration (2.2, 2.3), Warnings and Precautions (5.1)]. Neurological toxicities, including severe or life-threatening reactions, occurred following treatment with KYMRIAH, including concurrently with CRS. Monitor for neurological events after treatment with KYMRIAH. Provide supportive care and/or corticosteroids as needed [see Warnings and Precautions (5.2)]. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19- directed genetically modified autologous T cell immunotherapies, including KYMRIAH [see Warnings and Precautions (5.8)]. WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGICAL TOXICITIES, and SECONDARY HEMATOLOGICAL MALIGNANCIES See full prescribing information for complete boxed warning. Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving KYMRIAH. Do not administer KYMRIAH to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids. ( 2.2 , 2.3 , 5.1 ) Neurological toxicities, including severe or life-threatening reactions, occurred following treatment with KYMRIAH, including concurrently with CRS. Monitor for neurological events after treatment with KYMRIAH. Provide supportive care and/or corticosteroids as needed. ( 5.2 ) T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19- directed genetically modified autologous T cell immunotherapies, including KYMRIAH. ( 5.8 )
- brand names
- KYMRIAH
- current indication status
- not_reconciled
- dailymed set url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- generic names
- TISAGENLECLEUCEL
- id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- indications and usage exact
- 1 INDICATIONS AND USAGE KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. ( 1.1 ) Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitations of Use : KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1.3 ) 1.1 Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia KYMRIAH is indicated for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. 1.2 Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitation of Use: KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma. 1.3 Adult Relapsed or Refractory Follicular Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies (14.3)] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- indications and usage tables exact
- is original packager
- true
- manufacturer names
- Novartis Pharmaceuticals Corporation
- matched search terms
- lymphoma
- leukemia
- package ndcs
- 0078-0846-19
- 0078-0958-19
- product ndcs
- 0078-0846
- 0078-0958
- product types
- CELLULAR THERAPY
- recent major changes exact
- Boxed Warning 6/2025 Dosage and Administration ( 2.3 ) 6/2025 Warnings and Precautions ( 5.1 , 5.2 , 5.4 , 5.5 , 5.6 ) 12/2025 Warnings and Precautions, REMS (5.3) Removed 6/2025
- record type
- complete_spl_indications_section_candidate
- routes
- INTRAVENOUS
- rxcuis
- 1986442
- 1986447
- 2044973
- 2044975
- source batch
- file
- /private/tmp/cancer-full-research/indications/raw/labels-00200.json
- meta
- disclaimer
- Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
- last updated
- 2026-09-09
- results
- limit
- 100
- skip
- 200
- total
- 830
- sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl effective time
- 20251216
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- substance names
- TISAGENLECLEUCEL
- uniis
- Q6C9WHR03O
- verification flags
- oncology_keyword_candidate_not_clinically_classified
- spl_text_not_verified_identical_to_latest_approved_label
- individual_indications_not_split_or_reconciled
- no_matched_approved_submission
- application_missing_from_drugsfda_bulk
Drugs@FDA application source records
- application number
- BLA125646
- payload
- all indexed label documents
- all submission records
- application number
- BLA125646
- approval interpretation
- Application linkage and approved submission are not indication-level current approval verification
- current indication status
- not_reconciled
- drugsfda url
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125646
- has approved submission record
- false
- latest approved submission date
- Source null
- latest label selection rule
- max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
- latest posted label documents
- official application record
- Source null
- openfda application present
- false
- products
Source passages and status connections
Passage 1 · positive indication candidate
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 473
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. ( 1.1 ) Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, hi
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-153a23549c7ef96bc27c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-e1d02660f794836bbc1b
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- end
- 113
- end exclusive
- true
- exact text
- is a CD19-directed genetically modified autologous T cell immunotherapy indicated
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 32
- qualifier mentions
- context exact
- mmunotherapy indicated for the treatment of: Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) th
- kind
- age
- polarity
- not_inferred
- span
- end
- 166
- end exclusive
- true
- exact text
- 25 years of age
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 151
- context exact
- 1 INDICATIONS AND USAGE KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Patie
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 81
- end exclusive
- true
- exact text
- CD19-directed genetically modified autologou
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 37
- context exact
- B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 272
- end exclusive
- true
- exact text
- refractory or in second or later relapse
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 232
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 273
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 0
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 2 · unclassified context
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 481
- end exclusive
- true
- exact text
- tologous T cell immunotherapy indicated for the treatment of: Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. ( 1.1 ) Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 74
- current approval status
- not_reconciled
- duplicate text group
- dup-d8a4f82fedf02bcdcdc6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-6831bd34f2e1f1abaa2a
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 281
- end exclusive
- true
- exact text
- ( 1.1 )
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 274
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 3 · positive indication candidate
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 741
- end exclusive
- true
- exact text
- T cell immunotherapy indicated for the treatment of: Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. ( 1.1 ) Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitations of Use : KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma (FL) after
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 82
- current approval status
- not_reconciled
- duplicate text group
- dup-78d77b2dfea351b9b42c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-9263fc7f958e34d34329
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- end
- 113
- end exclusive
- true
- exact text
- is a CD19-directed genetically modified autologous T cell immunotherapy indicated
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 32
- qualifier mentions
- context exact
- Adult patients with relapsed or refractory (r/r) large B-cell lymphoma aft
- kind
- age
- polarity
- not_inferred
- span
- end
- 296
- end exclusive
- true
- exact text
- Adult patients
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 282
- context exact
- Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, includi
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 345
- end exclusive
- true
- exact text
- relapsed or refractory (r/r) large B-cell l
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 541
- end exclusive
- true
- exact text
- Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 282
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 4 · limitation of use
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 859
- end exclusive
- true
- exact text
- l lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitations of Use : KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 342
- current approval status
- not_reconciled
- duplicate text group
- dup-7a6c10cfba20ddfc5c4a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-4d5fd61f5e9cd6fdc869
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 659
- end exclusive
- true
- exact text
- Limitations of Use : KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma.
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 542
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 5 · unclassified context
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 867
- end exclusive
- true
- exact text
- specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitations of Use : KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and dura
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 460
- current approval status
- not_reconciled
- duplicate text group
- dup-29a9fa1c7847023da0c4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-c58f085bbfcd51827826
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 667
- end exclusive
- true
- exact text
- ( 1.2 )
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 660
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 6 · unclassified context
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 980
- end exclusive
- true
- exact text
- d, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitations of Use : KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of c
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 468
- current approval status
- not_reconciled
- duplicate text group
- dup-c8e93d482032d70b304c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-f66c6ac61db8cd3c0a24
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Adult patients with relapsed or refractory follicular lymphoma (FL) after
- kind
- age
- polarity
- not_inferred
- span
- end
- 682
- end exclusive
- true
- exact text
- Adult patients
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 668
- context exact
- Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 731
- end exclusive
- true
- exact text
- relapsed or refractory follicular lymphoma
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 688
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 780
- end exclusive
- true
- exact text
- Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 668
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 7 · approval contingency
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- approval_contingency_words
- clinical review status
- pending
- content role
- approval_contingency
- context span
- end
- 1084
- end exclusive
- true
- exact text
- icated for treatment of patients with primary central nervous system lymphoma. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1.3 ) 1.1 Pediatric and Young Adult Relapsed or Refractory B
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 581
- current approval status
- not_reconciled
- duplicate text group
- dup-9d1161bc8c47c65d6347
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-74b0bc1822dee58c5501
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 884
- end exclusive
- true
- exact text
- This indication is approved under accelerated approval based on response rate and duration of response.
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 781
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 8 · approval contingency
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- approval_contingency_words
- clinical review status
- pending
- content role
- approval_contingency
- context span
- end
- 1221
- end exclusive
- true
- exact text
- th relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1.3 ) 1.1 Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia KYMRIAH is indicated for treatment of patients up to 25 years of age with B-cell precursor acute lymph
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 685
- current approval status
- not_reconciled
- duplicate text group
- dup-c2839b6e3bda9165c42b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-34b4d7259c04c004ad2b
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 1021
- end exclusive
- true
- exact text
- Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 885
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 9 · unclassified context
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1229
- end exclusive
- true
- exact text
- ated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1.3 ) 1.1 Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia KYMRIAH is indicated for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 822
- current approval status
- not_reconciled
- duplicate text group
- dup-571b0a5de7ff40da7379
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-173567e4ad012ae078fe
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 1029
- end exclusive
- true
- exact text
- ( 1.3 )
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1022
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 10 · positive indication candidate
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1494
- end exclusive
- true
- exact text
- roval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1.3 ) 1.1 Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia KYMRIAH is indicated for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. 1.2 Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 830
- current approval status
- not_reconciled
- duplicate text group
- dup-13b6202b5c8eafdd4d15
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-0377ad6f240db9cddd17
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- end
- 1139
- end exclusive
- true
- exact text
- is indicated
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1127
- qualifier mentions
- context exact
- 1.1 Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphob
- kind
- age
- polarity
- not_inferred
- span
- end
- 1043
- end exclusive
- true
- exact text
- Pediatric
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1034
- context exact
- 1.1 Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- kind
- age
- polarity
- not_inferred
- span
- end
- 1059
- end exclusive
- true
- exact text
- Adult
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1054
- context exact
- ukemia KYMRIAH is indicated for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) th
- kind
- age
- polarity
- not_inferred
- span
- end
- 1187
- end exclusive
- true
- exact text
- 25 years of age
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1172
- context exact
- 1.1 Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia KYMRIAH is indicated for treatment of patien
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1103
- end exclusive
- true
- exact text
- Relapsed or Refractory B-cell Acute Lymphob
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1060
- context exact
- B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1293
- end exclusive
- true
- exact text
- refractory or in second or later relapse
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1253
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 1294
- end exclusive
- true
- exact text
- 1.1 Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia KYMRIAH is indicated for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1030
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 11 · positive indication candidate
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1855
- end exclusive
- true
- exact text
- Lymphoblastic Leukemia KYMRIAH is indicated for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. 1.2 Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitation of Use: KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma. 1.3 Adult Relapsed or Refractory Follicular Lymphoma KYMRIAH is indicated for treat
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1095
- current approval status
- not_reconciled
- duplicate text group
- dup-b120a3777cf41590cec4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-963852e1b133e0f128cd
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- end
- 1378
- end exclusive
- true
- exact text
- is indicated
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1366
- qualifier mentions
- context exact
- 1.2 Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma KYMRIA
- kind
- age
- polarity
- not_inferred
- span
- end
- 1304
- end exclusive
- true
- exact text
- Adult
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1299
- context exact
- Large B-cell Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma aft
- kind
- age
- polarity
- not_inferred
- span
- end
- 1410
- end exclusive
- true
- exact text
- adult patients
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1396
- context exact
- 1.2 Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma KYMRIAH is indicated for treatment of adult patien
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1348
- end exclusive
- true
- exact text
- Relapsed or Refractory Diffuse Large B-cell
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1305
- context exact
- a KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, includi
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1459
- end exclusive
- true
- exact text
- relapsed or refractory (r/r) large B-cell l
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1416
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 1655
- end exclusive
- true
- exact text
- 1.2 Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1295
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 12 · limitation of use
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 1971
- end exclusive
- true
- exact text
- l lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitation of Use: KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma. 1.3 Adult Relapsed or Refractory Follicular Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemi
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1456
- current approval status
- not_reconciled
- duplicate text group
- dup-5ac8b37581cea50f32d3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-f1ba572fd4743046864e
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 1771
- end exclusive
- true
- exact text
- Limitation of Use: KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma.
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1656
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 13 · positive indication candidate
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2181
- end exclusive
- true
- exact text
- e specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitation of Use: KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma. 1.3 Adult Relapsed or Refractory Follicular Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies (14.3)] . Continued approval for this indication may be contingent upon ve
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1572
- current approval status
- not_reconciled
- duplicate text group
- dup-310485786177a775e8d8
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-8523496d7feebadaa0d9
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- end
- 1845
- end exclusive
- true
- exact text
- is indicated
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1833
- qualifier mentions
- context exact
- 1.3 Adult Relapsed or Refractory Follicular Lymphoma KYMRIAH is indic
- kind
- age
- polarity
- not_inferred
- span
- end
- 1781
- end exclusive
- true
- exact text
- Adult
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1776
- context exact
- y Follicular Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL)
- kind
- age
- polarity
- not_inferred
- span
- end
- 1877
- end exclusive
- true
- exact text
- adult patients
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1863
- context exact
- 1.3 Adult Relapsed or Refractory Follicular Lymphoma KYMRIAH is indicated for treatment of adult patients with re
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1825
- end exclusive
- true
- exact text
- Relapsed or Refractory Follicular Lymphoma
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1782
- context exact
- a KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1926
- end exclusive
- true
- exact text
- relapsed or refractory (r/r) follicular lym
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1883
- regulatory links
- candidate source span
- end
- 1981
- end exclusive
- true
- exact text
- 1.3 Adult Relapsed or Refractory Follicular Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1772
- fda indication exact
- Treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy
- fda source row index
- 40
- fda source sha256
- 8df28be8da28c19a2d63f9c7ada45adf8aa0a5f11be1a2b4df67ce8eea572def
- fda status record id
- fda-aa-cce79c5ca7c6bc87f74f
- interpretation
- Source wording correspondence to a dated FDA status row; current approval not certified
- match method
- whole_indication_literal_normalized_substring
- matching review status
- source_comparison_only_clinical_review_pending
- scope relationship
- whole_fda_indication_text_present
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- status category
- ongoing
- status event date
- 2022-05-27
- supporting anchor spans
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 1981
- end exclusive
- true
- exact text
- 1.3 Adult Relapsed or Refractory Follicular Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1772
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Read indication-specific status → · whole_fda_indication_text_present
Passage 14 · approval contingency
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- approval_contingency_words
- clinical review status
- pending
- content role
- approval_contingency
- context span
- end
- 2253
- end exclusive
- true
- exact text
- Relapsed or Refractory Follicular Lymphoma KYMRIAH is indicated for treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies (14.3)] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1782
- current approval status
- not_reconciled
- duplicate text group
- dup-8871d4c518f15f34bba8
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-555a7ba094b4770b7434
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 2116
- end exclusive
- true
- exact text
- This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies (14.3)] .
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1982
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 15 · approval contingency
- application numbers
- BLA125646
- brand names
- KYMRIAH
- classification reasons
- approval_contingency_words
- clinical review status
- pending
- content role
- approval_contingency
- context span
- end
- 2253
- end exclusive
- true
- exact text
- cular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies (14.3)] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 1917
- current approval status
- not_reconciled
- duplicate text group
- dup-c2839b6e3bda9165c42b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- TISAGENLECLEUCEL
- id
- ind-span-84b2bd9c7ba0001f5149
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source defined aliases
- abbreviation
- FL
- definition exact
- follicular lymphoma
- definition span
- end
- 735
- end exclusive
- true
- exact text
- follicular lymphoma (FL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 711
- abbreviation
- R/R
- definition exact
- relapsed or refractory
- definition span
- end
- 330
- end exclusive
- true
- exact text
- relapsed or refractory (r/r)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 302
- abbreviation
- DLBCL
- definition exact
- diffuse large B-cell lymphoma
- definition span
- end
- 445
- end exclusive
- true
- exact text
- diffuse large B-cell lymphoma (DLBCL)
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 408
- source span
- end
- 2253
- end exclusive
- true
- exact text
- Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- label id
- 381f1ba3-f115-424f-9890-75eb06ab6666
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- a9debacdb256ddbeb9b9206a786252d6198d6084a56e17e3eb1aad2bdd76b7de
- start
- 2117
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22381f1ba3-f115-424f-9890-75eb06ab6666%22
- spl effective date
- 2025-12-16
- spl set id
- aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
- spl version
- 18
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Preserved source evidence · Not medical advice